Genzyme Executive VP-Legal And Corporate Development Peter Wirth: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Wirth discusses personalized medicine and Genzyme’s development pipeline, including further plans for Mozobil.
You may also be interested in...
Genzyme Reports Positive Phase III Results For Mozobil In Stem Cell Transplant
NDA filing for patients undergoing hematopoietic stem cell transplant for NHL is anticipated in first half of 2008.
Genzyme Reports Positive Phase III Results For Mozobil In Stem Cell Transplant
NDA filing for patients undergoing hematopoietic stem cell transplant for NHL is anticipated in first half of 2008.
Genzyme Executive VP-Legal And Corporate Development Peter Wirth: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Wirth talks about Genzyme’s contentious acquisition of AnorMED and current shareholder objections to the company’s bid to acquire clofarabine partner Bioenvision.